(Alliance News) - Faron Pharmaceuticals Oy on Tuesday said it has raised EUR2.5 million via share subscription and open offer.The company raised EUR1.0 million from the issue of 859,513 at Read More
(Alliance News) - Faron Pharmaceuticals Oy on Monday announced a EUR1.1 million subscription and EUR2.0 million open offer to fund the clinical development of cancer drug Clevegen.Shares in Read More
(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - WINNERS----------BHP up 1.5%. The - Read More
(Alliance News) - Faron Pharmaceuticals Oy said on Friday its MATINS study of nine cancer patients is progressing well, and it is planning to expand the clinical trial to more countries.The Read More
(Alliance News) - Faron Pharmaceuticals Oy on Wednesday said interim results from its phase two Inforaaa study support continuation but the study is limited by a lack of patients not also taking a Read More
(Alliance News) - Faron Pharmaceuticals Oy on Friday said analysis of a more recent trial of Traumakine has explained why the drug did not perform as expected in a previous trial.Shares in Read More
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Friday said it has made several managerial changes, which it believes will strengthen its operating performance.The clinical stage said Read More
LONDON (Alliance News) - Biopharmaceutical company Faron Pharmaceuticals Ltd said Tuesday that it has raised EUR1.3 million via share subscription.The company has issued 1.8 million shares Read More
LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Tuesday reported a slightly narrowed annual loss as the drug developer's research & development costs fell.Faron is a clinical Read More
LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it is unable to explain the recent movement in its share price.Faron noted Thursday's 43% share price rise, and said Read More
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said its Japanese licensing partner Maruishi Pharmaceutical Co Ltd has provided clinical trial results on its phase three Traumakine for Read More
LONDON (Alliance News) - Faron Pharmaceuticals Oy is to target colorectal cancer in its upcoming test programme for Clevegen, it said Thursday.The testing of Clevegen on patients with will Read More
LONDON (Alliance News) - Finland's Faron Pharmaceuticals Oy on Tuesday afternoon said it has raised EUR3.1 million pursuant to a placing announced earlier in the day.The company issued Read More
LONDON (Alliance News) - Finland's Faron Pharmaceuticals Oy on Tuesday said it expects further disappointing results from Traumakine, as it plans a share placing.Faron is currently for Read More
LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Thursday said early results from a trial of its Clevegen cancer drug are encouraging.Shares in Faron were up 10% at 64.00 pence on said Read More
LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Wednesday said new data supports the use of Clever-1 antibodies in re-activating an immune response to tumours.Shares in Faron were up Read More
LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - up 2.7%. Japan's Takeda Pharmaceutical Read More
LONDON (Alliance News) - Faron Pharmaceuticals Ltd shares jumped on Wednesday as the company said it identified an "optimal" subgroup of patients, with a certain genetic mutation, to be Read More
